Résumé
Objectif
L’élévation sérique de l’antigène spécifique de la prostate (PSA) est révélatrice de pathologies prostatiques. L’âge, chez un homme, peut entraîner des fluctuations de concentration du PSA. L’objectif de cette étude est d’évaluer les relations entre l’âge et les paramètres clinique et biologique en cas d’hypertrophie bénigne de la prostate (HBP).
Matériel et méthodes
Un échantillon de 67 cas d’HBP, âgés de plus de 50 ans, a été diagnostiqué dans le service d’urologie de l’hôpital de Saïda entre 2007–2008. Les patients ont subi un dosage de PSA total (PSAT) alors que le PSA libre (PSAL) n’a été réalisé que chez 23,8 % des patients.
Résultats
L’âge moyen des patients était de 72,9 ans. Dans 82 % des cas, PSAT > 4 ng/ml dont 37,3 % avec un PSAT > 10 ng/ml. L’âge ne montre pas de corrélations avec le poids prostatique (PP) (r = 0,026, p > 0,05) et PSAT (r = − 0,036, p > 0,05) par contre il existe une corrélation significative entre PP et PSAT (r = 0,49, p < 0,01). Le ratio (PSAL / PSAT) moyen était de 54,23 % et plus de 40 % des patients avaient un PSAT entre 4–10 ng/ml dont 31 % avaient un ratio > 15 %.
Conclusion
Ces résultats suggèrent une éventuelle existence d’HBP pour des valeurs de PSAT entre 4–10 ng/ml associées à une augmentation du PP et un ratio supérieur à 15 %.
Abstract
Objective
Serum rising of prostate specific antigen (PSA) is revealing of prostate pathologies. Age may cause fluctuations of PSA concentration. The objective of this study is to assess the relations between the age, clinical and biological parameters in case of benign prostate hyperplasia (BPH).
Material and methods
A sample of 67 cases, aged over 50 years, was diagnosed in the urology service of Saïda hospital between 2007–2008. The patients underwent a total PSA (TPSA) serum assay whereas a free PSA (FPSA) was carried out only for 23.8% of patients.
Results
The average age was 72.9 years. TPSA was beyond 4 ng/ml for 82% of patients which 37,3% had TPSA higher than 10 ng/ml. The age doesn’t show correlation with prostatic weight (PW) (r = 0.026, p > 0.05) and TPSA (r = − 0.036, p > 0.05) but there is a significant correlation between PW and TPSA (r = 0.49, p < 0.01). The free fraction (FPSA/ TPSA) average was 54.23% and more than 40% of the patients had TPSA between 4–10 ng/ml whose 31%had a free fraction > 15%.
Conclusion
These results show the presence of BPH for TPSA values between 4–10 ng/ml associated with rising of the PW and a free fraction higher than 15%.
This is a preview of subscription content, access via your institution.
Références
Bo M, Ventura M, Marinello R, et al (2003) Relationship between prostatic specific antigen (PSA) and volume of the prostate in the benign hyperplasia in the elderly. Crit Rev Oncol Hematol 47:207–211
Chautard D, Bocquillon V, Daver A, et al (2000) Est-il possible de définir un seuil de l’index de PSA libre utile en pratique urologique quotidienne ? Prog Urol 10:571–577
Janssen T, Schulman C (1994) Antigène prostatique spécifique: un bilan 15 ans après sa découverte. Prog Urol 4:171–180
Coussa L, Machuca S, Gauchez AS (2006) Le dépistage du cancer de la prostate en 2005: quelle place pour le PSA ? IBS 21:105–109
Catalona WJ, Partin AW, Slawin KM, et al (1998) Use of the percentage of the free prostate-specific antigen to enhance the differenciation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547
Fulla Y, Noel M, Le Brun G (2008) Optimisation de l’utilisation du PSA. Médecine nucléaire 32:31–40
Rhodes T, Girman CJ, Jacobsen SJ, et al (1999) Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J urol 161:1174–1179
Jakobsen H, Torp-pederson S, Juul N (1998) Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. Scand J Urol Nephrol suppl. 107:26
Roherborn CG, Boyle P, Gould L, Waldstreicher J (1998) Serum prostate specific antigen as predictor of prostate volume in men with benign prostate hyperplasia. Urol 53:581–589
Hammerer PG, McNeal JE, Stamey TA (1995) Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J urol 153:111–114
Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923
Dalkin B, Ahmann F, Southwick P, Bottaccini M (1993) Derivation of normal prostate specific antigen (PSA) level by age. J Urol 149:413
Rietbergen JBW, Kranse R, Hoedemaeker RF, et al (1998) Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study. Urology 52:237–246
Bosch JLHR, Hop VJW, Bangma CH, et al (1995) Prostate specific antigen in a community-based of men without prostate cancer: correlation with prostate volume, age, body mass index and symptoms of prostatism. Prostate 27:241–249
Kirillos MM (1996) Prostate-specific antigen and age. Is there a correlation? And why does it seem to vary? Eur Urol 30:296–301
Densel A, May P (1991) Die Beeinflussung des PSA-Wertes durch benign Prostataerkrankungen. Urologe [B] 31:217
Collins GN, Lee RJ, McKelvie GB, et al (1993) Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 71:455
Heuzé-Vourc’h N, Courty Y (2001) Les formes circulantes du PSA. Immunoanal Biol Spéc 16:295–301
Fong CJ, Sherwood ER, Braun EJ, et al (1992) Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions. Prostate 21:121
Gambert SR (2001) Prostate cancer. When to offer screening in the primary care setting. Geriatrics 56:22–31
Harris RP, Lohr KN (2002) Screening for prostate cancer: an uptade of the evidence for the U.S. preventive services task force. Ann Int Med 137:917–929
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Berroukche, A., Bendahmane-Salmi, M. & Kandouci, A.B. Relation entre l’âge et les paramètres clinique et biologique. À propos de 67 cas d’hypertrophie bénigne de la prostate dans un hôpital ouest-algérien. J Afr Cancer 5, 198–203 (2013). https://doi.org/10.1007/s12558-013-0281-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12558-013-0281-x